H
#CardiovascularHealth #ObesityManagement #GLP1
health.usnews.com
GLP-1 Drugs for Heart Health: Benefits, Side Effects & Who Should Take Them
Cardiologists and obesity medicine physicians alike are hopeful about these preliminary findings. However, lifestyle habits, including getting adequate sleep, eating healthy and exercising, are still the top ways to stave off cardiovascular disease.
#ObesityTreatment #WeightLoss #FDAApproval
www.yahoo.com
FDA approves Allurion's PMA application for Gastric Balloon System
Allurion's founder and CEO Dr Shantanu Gaur stated that the Smart Capsule offers a safe and effective alternative to GLP-1s and bariatric surgery, aiming to provide metabolically healthy weight loss and become a standard tool in obesity treatment in the US.
#EliLilly #Zepbound #ObesityTreatment
www.cnbc.com
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024.
Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen.
#Obesity #HealthInnovation #PersonalizedMedicine
www.forbes.com
How GLP-1 Weight Loss Drugs Have Revolutionized Obesity- Lessons Learned
The blockbuster weight loss GLP-1 drugs such as Wegovy and Zepbound have revolutionized obesity, the way healthcare workers and patients think about the disease and the way it is treated.
#Obesity #HealthInnovation #PersonalizedMedicine
www.forbes.com
How GLP-1 Weight Loss Drugs Have Revolutionized Obesity- Lessons Learned
The blockbuster weight loss GLP-1 drugs such as Wegovy and Zepbound have revolutionized obesity, the way healthcare workers and patients think about the disease and the way it is treated.
#HealthInsurance #GLP1 #ObesityTreatment
news.harvard.edu
Pricey blockbuster GLP-1s are costing users -- and most of the rest of us, too -- Harvard Gazette
Health insurers are passing along cost for coverage in form of higher rates across the board, policy researcher says
The popularity of pricey GLP-1 drugs has hit the budgets of users -- and just about everyone else.
#Obesity #PublicHealth #Nutrition
abcnews.go.com
Obesity to rise by 19 million and affect 126 million American adults by 2035, new study finds
Researchers reviewed the body mass index of over 11 million Americans.
The number of Americans living with obesity is expected to rise by 19 million and affect nearly 126 million people by 2035, according to a new study published in the Journal of the American Medical Association on Wednesday.
#CardiovascularHealth #ObesityTrends #YoungAdultsHealth
ca.style.yahoo.com
Heart health is improving overall. So why are strokes rising among young adults?
Add Yahoo as a preferred source to see more of our stories on Google.
By some measures, young adults in the U. S. are healthier -- or at least more health-conscious, judging by their spending on wellness goods and services, as well as social media posts -- than previous generations.
#Obesity #PublicHealth #ChronicConditions
nypost.com
Ozempic who? Nearly half of American adults will be obese by 2035:...
America's obesity problem is tipping the scales.
A new study found that the share of US adults living with obesity has more than doubled over the past three decades, ballooning from 19% in 1990 to 42% in 2022.
W
#WeightLoss #ObesityManagement #GLP1Medications
www.wsj.com
Here's What Happens When You Stop Taking Ozempic and Wegovy
Studies show that after stopping the drugs, people typically regain lost weight within about 1. 5 years. Peter Dazeley/Getty Images
A recent email ad from a telehealth company selling weight-loss medications features tennis-superstar Serena Williams.
#FoodAddiction #ObesityCrisis #PublicHealth
nypost.com
RFK Jr. blames Big Tobacco for addictive food that has Americans...
Health and Human Secretary Robert Kennedy Jr. blamed the major tobacco companies for manufacturing bad, ultra-processed addictive food that has fueled obesity, chronic disease and even "poisoned" Americans.
